ClinicalTrials.gg
Active, not recruitingNCT07708506HOMELANDUpdated Jul 17, 2026

Is Hypoxemia Driving Outcome in Acute Hypoxemic Respiratory Failure? (HOMELAND Study)

An observational study in Acute Hypoxemic Respiratory Failure, sponsored by Jesus Villar. Active, not recruiting at 18 sites in 2 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Jesus Villar · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,241
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Respiratory Insufficiency with a site in Spain — 11 open to participants now, 15 under way, none of them phase 3. Respiratory Insufficiency · Spain.

Planned enrollment
6th of 31
1,241 · median 298
Started
2026
with 4 others
Observational
31 of 69
5 open now
Primary completion
2027-07
later than 9 of 14 live
Registered
67th of 69
by date
Lead sponsor
2 of 69
Jesus Villar

Among the 69 studies in Respiratory Insufficiency with a site in Spain, this one is the 6th largest by planned enrollment of the 31 observational ones that give a count, is one of 5 that started in 2026, is one of 31 observational ones, reaches primary completion later than 9 of the 14 other live ones, and was the 67th registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

11 of the 69 studies in Respiratory Insufficiency with a site in Spain are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Respiratory Insufficiency with a site in Spain, or all of them as a file.
02

Study summary

Acute hypoxemic respiratory failure (AHRF) is the most common cause of admission in the intensive care units (UCIs) worldwide. The investigators will assess the value of mediation analysis (a statistical method to understand the mechanism or process through which an independent variable influences a dependent variable (prediction of early ICU death) via a mediator variable. This allows researcher to see the "how" and "why" of a causal link, respecting the timing relationships" o "maintaining appropriate time constants in patients with AHRF me, We had a database with 2,000,000 anonymized and dissociated demographics and clinical data from 1,241 patients with AHRF enrolled in our PANDORA cohort (Prevalence AND Outcome of acute Respiratory fAilure) registered with ClinicalTrails.gov (NCT013145974) from 22 Spanish hospitals and funded by the ISCIII. The study was approved by the Ethics Committees for Clinical research of participating hospitals and informed consent was waived based on Spanish legislation for biomedical research (Royal Decrees 1090/2015 and 957/2020). The investigators will use mediation analysis (Baron \& Kenny techniques) to clarify the association of extrapulmonary organ dysfunction and hypoxemia in the early prediction of ICU mortality. We will analyze 1,241 patients mechanically ventilated with AHRF at the time of diagnosis, 1,193 with data at 24 hours, and 996 patients with data at 48 hours from a epidemiological study in Spain.

Read the detailed description

Background: Acute hypoxemic respiratory failure (AHRF) is the most common cause of admission in the intensive care units (UCIs) worldwide.

Objectives: The investigators will asess the value of mediation analysis (a statistical method to understand the mechanism or process through which an independent variable influences a dependent variable (prediction of early ICU death) via a mediator variable. This allows researcher to see the "how" and "why" of a causal link, respecting the timing relationships" o "maintaining appropriate time constants in patients with AHRF mechanically ventilated.

Methods: The investigators had a database with 2,000,000 anonymized and dissociated demographics and clinical data from 1,241 patients with AHRF enrolled in our PANDORA cohort (Prevalence AND Outcome of acute Respiratory fAilure) from 22 Spanish hospitals and funded by the ISCIII. The study was approved by the Ethics Committees for Clinical research of participating hospitals and informed consent was waived based on Spanish legislation for biomedical research (Royal Decrees 1090/2015 and 957/2020). The investigators will use mediation analysis (Baron \& Kenny techniques) to clarify the association of extrapulmonary organ dysfunction and hypoxemia in the early prediction of ICU mortality. The investigators will analyze 1,241 patients mechanically ventilated with AHRF at the time of diagnosis, 1,193 with data at 24 hours, and 996 patients with data at 48 hours from a epidemiological study in Spain.

03

Conditions studied

  • Acute Hypoxemic Respiratory Failure

Keywords

  • mechanical ventilation
  • mediation analysis
  • outcome
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Critically ill patients, intubated and mechanically ventilated, with acute hupoxemic respiratory failure (AHRF)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • intubation and mechanical ventilation PaO2/FiO2 ratio \< or = 300 mmHg under MV with PEEP > or = 5 cmH2O, and FiO2 > 0r = 0.3

Exclusion criteria

Exclusion Criteria:

  • Brain death patients
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,241 participants (estimated)
Patient registry
No

Groups and cohorts

  • Time on admission

    The investigators will use 1241 at the time of meeting AHRF (t0)

    Diagnostic Test: mediation analysis

  • Time 24

    The investigaotros will use 1193 patients with AHRF, with completed data after 24 hours of mechanical ventilation

    Diagnostic Test: mediation analysis

  • Time 48

    The investigaotros will use 996 patients with AHRF with completed data after 48 hours of mechanical ventilation

    Diagnostic Test: mediation analysis

Interventions

  • Diagnostic testmediation analysis

    This allows researcher to see the "how" and "why" of a causal link, respecting the timing relationships" o "maintaining appropriate time constants in patients with AHRF mechanically ventilated.

06

What researchers measure

Primary outcomes

  1. Death in the intensive care unit (ICU)

    prediction of ICU death

    Time frame: up to 100 weeks

07

Study locations

18 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2027, 12 months after the start.

Of 232 non-industry observational studies under Respiratory Insufficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's planned 12 months is below that.

Counting every sponsor, half of 248 studies reached it within 22 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 16, 2026
StartActual
Jul 13, 2026
Primary completionEst.
Jul 29, 2027
CompletionEst.
Jul 29, 2027
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07708506
Lead sponsor
Jesus Villar
Collaborators
Hospital Universitario de Gran Canaria Doctor Negrín
Responsible party
Jesus Villar (Principal investigator and scientificc advisor, Hospital Universitario de Gran Canaria Doctor Negrín) — Sponsor-investigator
First posted
Jul 16, 2026
Start date
Jul 13, 2026
Primary completion
Jul 29, 2027 (estimated)
Completion
Jul 29, 2027 (estimated)
Last update
Jul 17, 2026

Study contacts

Jesus Villar
study chair · Research Unit, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion